Skip to main content
ANAB
NASDAQ Life Sciences

EcoR1's Oleg Nodelman Buys $17.2M of AnaptysBio Stock in Three-Day Open-Market Run

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$47.06
Mkt Cap
$1.399B
52W Low
$22.063
52W High
$72.36
52W Position info
113% above low
Off High info
35% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ANAB has more than doubled off its 52-week low of $22.063.

Summary

Director and 10% owner Oleg Nodelman (EcoR1 Capital) bought 374,580 AnaptysBio shares for $17.2 million in open-market trades on November 16-18, raising the stake to 8.25 million shares.


Key Events · Ownership and Investor Activity · ANAB

  • Insider Buys $17.2M in Open Market

    EcoR1 Capital and Oleg Nodelman acquired 374,580 shares across three transactions from 2026-11-16 to 2026-11-18 at prices between $45.66 and $46.54, totaling $17,224,592.78.

  • Stake Rises to 8.25 Million Shares

    Post-transaction holdings reached 8,254,674 shares, with the Qualified Fund holding 7,642,937 of them after the final purchase.

  • Buying Into Delaware Litigation Risk

    The purchases came after shares dropped 8% on 2026-10-20 when the Delaware Chancery hearing over the dostarlimab contract dispute began; the ruling is still pending per the Q3 10-Q.

  • Fund Manager, Not Operating Executive

    Nodelman is a director and 10% owner through EcoR1 Capital, so the purchase reflects a large holder's conviction rather than an operating officer's view.


Analysis · ANAB · Life Sciences

A director and 10% owner put $17.2 million of real money into the open market over three consecutive sessions, lifting the EcoR1-linked stake to 8.25 million shares. That is a large, unplanned purchase rather than an option exercise or grant, and it lands while AnaptysBio waits on a Delaware Chancery ruling over dostarlimab rights and after the stock fell 8% when that hearing began. Buying into that uncertainty is the strongest insider conviction signal the company has produced recently, though the buyer is a fund manager rather than an operating executive, so read it as a major holder defending and adding to its position rather than as management guidance.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANAB was trading at $47.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $22.06 to $72.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANAB - Latest Insights

ANAB
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $47.74 info
Change: -$0.030 (-0.06%) info
Market Cap: $1.399B info
ANAB
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $47.74 info
Change: -$0.030 (-0.06%) info
Market Cap: $1.399B info
ANAB
Oct 20, 2026, 3:49 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $45.00
Real-time Price: $47.74 info
Change: +$2.74 (+6%) info
Market Cap: $1.399B info
ANAB
Oct 19, 2026, 2:18 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $49.23
Real-time Price: $47.74 info
Change: -$1.49 (-3%) info
Market Cap: $1.399B info
ANAB
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $50.85
Real-time Price: $47.74 info
Change: -$3.11 (-6%) info
Market Cap: $1.399B info